Article
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2010
Ready Neal, Jänne Pasi A, Bogart Jeffrey, Dipetrillo Thomas, Garst Jennifer, Graziano Stephen, Gu Lin, Wang Xiaofei, Green Mark R, Vokes Everett E
Abstract excerpt
INTRODUCTION: This study evaluated the addition of gefitinib to sequential or concurrent chemoradiotherapy (CRT) in unresectable stage III non-small cell lung cancer. METHODS: Between May 2002 and April 2005, 63 patients were entered before the study closing early. All received two cycles paclitaxel 200 mg/m and carboplatin area under the curve 6 intravenous plus gefitinib 250 mg daily. Poor risk stratum 1 (> or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.